// App-Quantinova.ai

4003 : KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.

Researchers

Presenter

  • Charles S. Fuchs

Principal Investigators

  • Raymond Woo-Jun Jang

  • Kei Muro

  • Taroh Satoh

  • Manuela Machado

  • Weijing Sun

  • Shadia Ibrahim Jalal

  • Manish A. Shah

  • Jean-Philippe Metges

  • Marcelo Garrido

  • Talia Golan

  • Mario Mandala

  • Zev A. Wainberg

  • Daniel V.T. Catenacci

  • Yung-Jue Bang

  • Jiangdian Wang

  • Minori Koshiji

  • Rita P. Dalal

  • Harry H. Yoon

Medical Centers

  • Yale Cancer Center, New Haven, CT

  • National Cancer Center Hospital, Tokyo, Japan

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Aichi Cancer Center Hospital, Nagoya, Japan

  • Osaka University Graduate School of Medicine, Suita, Japan

  • Portuguese Institute of Oncology, Lisbon, Portugal

  • University of Pittsburgh Medical Center, Pittsburgh, PA

  • Indiana University School of Medicine, Indianapolis, IN

  • Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY

  • Centre Hospitalier Regional Universitaire (CHRU) de Brest - Hopital Morvan, Brest, France

  • Pontificia Universidad Catolica de Chile, Santiago, Chile

  • Sheba Medical Center Hospital at Tel HaShomer, Tel-Hashomer, Israel

  • Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy

  • Ronald Reagan UCLA Medical Center, Los Angeles, CA

  • University of Chicago Pritzker School of Medicine, Chicago, IL

  • Merck & Co., Inc., Kenilworth, NJ

  • Mayo Clinic, Rochester, MN

Locations

  • Canada

  • Japan

  • Italy

  • United States

  • Portugal

  • Israel

  • France

  • Chile

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • NCT02335411

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved